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We thank Teoh [1_TD$DIFF]and [2_TD$DIFF]colleagues for their letter regarding our
recent report [1]. They acknowledge that multiparametric
magnetic resonance imaging (mpMRI) of the bladder has
great potential for staging in urinary bladder cancer (UBC).
However, they raise several points regarding the current
approach to UBC diagnosis and the possible role of mpMRI.
We recognize, as has been widely demonstrated [2], that
diagnosis of UBC is not straightforward. Moreover, for Ta–T1
lesions, there is significant risk of residual disease after initial
transurethral resection of bladder tumor (TURBT) [3] and the
risk of understaging is not negligible [4]. For these reasons, a
second TURBT is strongly recommended after incomplete
resection of the lesion, if there is no muscle in the specimen
after initial resection, and for T1 tumors [5]. In addition,
pathologic staging of radical cystectomy specimens can be
challenging, especially when differentiating stages pT2b and
pT3a, with important clinical implications [6,7].
Given all the limitations of the current approach to UBC
diagnosis, TURBT, and en-bloc resection of bladder tumor
(EBRT) in selected cases, remains the gold standard for
diagnosis, and no imaging technique alone can justify any
radical treatment or chemotherapywithout histologic proof
[5]. Patient management is based on histopathologic
evaluation of TURBT specimens, and therefore any imaging
technique aimed at improving the UBC diagnosis pathway
should be validated against TURBT and possibly EBRT. We
actually believe that the availability of two consecutive
diagnostic procedures in all patients deemed at high risk of
underdiagnosis and/or residual disease canmake validation
of the Vesical Imaging-Reporting and Data System (VI-
RADS) even more accurate, provided that patients undergo
mpMRI before any invasive procedure.
Even though we state that mpMRI should be performed
at least 2 wk after TURBT, we would like to highlight that aDOI of original article: https://doi.org/10.1016/j.eururo.2018.09.007.
https://doi.org/10.1016/j.eururo.2018.09.032
0302-2838/© 2018 Published by Elsevier B.V. on behalf of European Associarecently treated patient is not an ideal candidate formpMRI.
In selected cases, imaging can be helpful for planning
repeat TURBT; however, as previously reported [8], the aim
of VI-RADS is to generate a score for untreated patients to
differentiate Ta–T1 from T2 or higher tumors. If the ability of
VI-RADS to identify bladder muscle invasion is confirmed,
patients with muscle-invasive bladder cancer (MIBC) could
be directed to a diagnostic TURBT to expedite radical
treatment whenever possible. Similarly, if the ability of
mpMRI to exclude MIBC is established, a proportion of
patients could possibly be spared a second TURBT.
Furthermore, the aim of VI-RADS is to standardize mpMRI
terminology and image acquisition techniques for UBC,
reduce inter-reader variability, and improve communica-
tion between radiologists and urologists. Furthermore,
VI-RADS is a risk assessment tool that should always be
used in conjunction with clinical, surgical, and histopatho-
logic diagnostic techniques.
We agree with the authors that mpMRI could also be
used to differentiate between Ta and T1 disease because of
the important therapeutic implications; however, given the
limited spatial resolution of mpMRI, focused studies will be
needed to test its potential in this regard. At present, any
information attempting to distinguish between different
categories of non–muscle-invasive bladder tumor should be
interpreted with caution. Probably more relevant is the use
of mpMRI in the setting of bladder-sparing trimodal
therapy, in which it could help to improve patient selection
and subsequent management (ie, by directing endoscopic
surgery) and follow-up.
In conclusion, we agree with Teoh [1_TD$DIFF]and [2_TD$DIFF]colleagues on the
paramount need for high-quality trials aimed at validating
the VI-RADS. However, we believe that at present, the most
widespread and reliable diagnostic technique for validating
any imaging score is TURBT and therefore it cannot be set
aside despite its important limitations.
Conflicts of interest: The authors have nothing to disclose.
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